The Redemption of James Wilson, Gene Therapy Pioneer

September 13, 2019

(Chemical & Engineering News) – For anyone familiar with the slow crawl of drug development, gene therapy is moving at lightning speed. The approval of the first two gene therapies in the US and promising clinical data on many more have supercharged the field. Money, hard to raise not long ago, is flooding into academic labs and companies developing gene therapies. The FDA can barely keep up with the growing pipeline, and it anticipates receiving more than 200 applications from groups that want to test new cell and gene therapies next year. The pace is a source of both excitement and anxiety for anyone who’s weathered gene therapy’s peaks and troughs over the past 3 decades. And of all the field’s pioneers, 64-year-old Wilson may feel that tension more strongly than anyone.

Recommended Reading